Neurons Fight Back: Innate Immunity and Cell Death in ALS
July 22, 2025
A research consortium led by MGH and Harvard is reshaping how we think about inflammation in ALS, not just as a reaction to dying nerve cells, but as a neuron-driven immune response that may actually be fueling disease progression.
Their work shows that neurons, like all cells, have innate immune pathways; built-in defense systems that help them respond to stress, viral threats, and damage. But in ALS, these pathways may go rogue.
- ALS 101:
- Innate Immunity: The body’s first line of defense; quick, general responses to threats like viruses or injury, built into every cell.
- TDP-43: A protein that regulates gene activity. In ALS, it moves to the wrong part of the cell, disrupting normal function.
- C9orf72 DPRs: Toxic protein-like fragments caused by a genetic mutation, common in familial ALS cases.
- GSDME (Gasdermin E): A protein that can form pores in cell membranes, causing inflammation and cell death.
- Knockdown (KD): A method scientists use to reduce the activity of a gene to study or treat disease.
Using neurons derived from patients and in vivo mouse models, the team has pinpointed key immune sensors; STING, RIG-I/MAVS, and especially Gasdermin E (GSDME) as central players. These sensors are activated by known ALS-related stressors like TDP-43 mislocalization and C9orf72 dipeptide repeats (specifically PR50).
One of their most striking findings: GSDME, a protein that punches holes in cell membranes, is a major driver of mitochondrial damage and neuronal death in ALS. When researchers knocked down GSDME, they were able to rescue motor neurons and even reverse behavioral symptoms in mouse models, making it a high-potential therapeutic target.
They’ve also begun exploring how GSDME activation may amplify immune responses, possibly even drawing in T cells and linking to broader immune system activity. Early safety signals are encouraging: mice lacking GSDME appear largely normal, suggesting that targeting it in patients might be both effective and safe.
💡 Key Takeaway:
By uncovering how neurons’ own immune systems can trigger their death in ALS, and showing that turning off GSDME can stop this process, this team is opening up a whole new avenue for ALS therapies. Instead of just managing symptoms, we may soon be able to shut down the disease at its source.
Related News
Inside a Global Effort to Understand ALS Resilience
January 27, 2026
